Načítá se...
Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma
Immunotherapy of advanced melanoma with CTLA-4 or PD-1/PD-L1 checkpoint blockade induces in a proportion of patients long durable responses. In contrast, targeting the MAPK-pathway by selective BRAF and MEK inhibitors induces high response rates, but most patients relapse. Combining targeted therapy...
Uloženo v:
| Vydáno v: | Oncoimmunology |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Taylor & Francis
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5215252/ https://ncbi.nlm.nih.gov/pubmed/28123875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2016.1238557 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|